Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Job title: Interventional Cardiologist
Dr David Power is an Interventional Cardiologist at Mount Sinai Queens and an Assistant Professor of Medicine at the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai, NY. Dr Power's clinical interests include coronary artery disease, coronary calcium, stent technology, and peripheral arterial disease.Dr Power completed his residency in Internal Medicine, followed by a Cardiology… View more
Added: 1 year ago
In this week's episode, Dr Ankur Kalra welcomes authors Dr Srihari Naidu and Lindsay Davis to discuss their newly published children's book, Lindsay's Big Heart. A leading interventional cardiologist, Dr Naidu, and patient advocate, Ms Davis, have collaborated to bring the complex heart condition hypertrophic cardiomyopathy (HCM) to life for young readers.Lindsay Davis shares her personal journey… View more
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes… View more
Author(s): Carolyn Lam , Giuseppe Rosano Added: 2 years ago
In this short video series, recorded at ESC 2023 in Amsterdam,Prof Carolyn Lam(National Heart Centre Singapore, SG) and Prof Giuseppe Rosano(St George’s University Medical School of London, UK) discuss the latest heart failure guideline updates and what this means for clinical practice. Since the publication of the 2021 ESC Guidelines, several randomised controlled trials have provided… View more
Author(s): Milind Y Desai Added: 6 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more
Author(s): Gregory Lewis Added: 4 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance… View more
High TnI after OPCABG

Original Research

Author(s): Hao Cui , Jinwei Zhang , Jianbo Yu , et al Added: 6 months ago
Author(s): Harriette Van Spall , James L Januzzi Added: 1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,… View more